<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35328793</PMID><DateCompleted><Year>2022</Year><Month>04</Month><Day>08</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>08</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>23</Volume><Issue>6</Issue><PubDate><Year>2022</Year><Month>Mar</Month><Day>21</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>The Expression of Active CD11b Monocytes in Blood and Disease Progression in Amyotrophic Lateral Sclerosis.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">3370</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms23063370</ELocationID><Abstract><AbstractText>Monocytes expressing the inflammation suppressing active CD11b, a beta2 integrin, may regulate neuroinflammation and modify clinical outcomes in amyotrophic lateral sclerosis (ALS). In this single site, retrospective study, peripheral blood mononuclear cells from 38 individuals living with ALS and 20 non-neurological controls (NNC) were investigated using flow cytometry to study active CD11b integrin classical (CM), intermediate (IM) and non-classical (NCM) monocytes during ALS progression. Seventeen ALS participants were sampled at the baseline (V1) and at two additional time points (V2 and V3) for longitudinal analysis. Active CD11b+ CM frequencies increased steeply between the baseline and V3 (ANOVA repeated measurement, p &lt; 0.001), and the V2/V1 ratio negatively correlated with the disease progression rate, similar to higher frequencies of active CD11b+ NCM at the baseline (R = &#x2212;0.6567; p = 0.0031 and R = 0.3862; p = 0.0168, respectively). CD11b NCM, clinical covariates and neurofilament light-chain plasma concentration at the baseline predicted shorter survival in a multivariable and univariate analysis (CD11b NCM&#x2014;HR: 1.05, CI: 1.01&#x2212;1.11, p = 0.013. Log rank: above median: 43 months and below median: 21.22 months; p = 0.0022). Blood samples with the highest frequencies of active CD11b+ IM and NCM contained the lowest concentrations of soluble CD11b. Our preliminary data suggest that the levels of active CD11b+ monocytes and NCM in the blood predict different clinical outcomes in ALS.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yildiz</LastName><ForeName>Ozlem</ForeName><Initials>O</Initials><Identifier Source="ORCID">0000-0003-0590-049X</Identifier><AffiliationInfo><Affiliation>Centre for Neuroscience, Surgery and Trauma, The Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London E1 2AT, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuromuscular Department, Queen Square Motor Neuron Disease Centre, Institute of Neurology, University College London, London WC1N 3BG, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schroth</LastName><ForeName>Johannes</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Translational Medicine and Therapeutics, William Harvey Research Institute, Barts and the London, Queen Mary University of London, London EC1M 6BQ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lombardi</LastName><ForeName>Vittoria</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Centre for Neuroscience, Surgery and Trauma, The Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London E1 2AT, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuromuscular Department, Queen Square Motor Neuron Disease Centre, Institute of Neurology, University College London, London WC1N 3BG, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pucino</LastName><ForeName>Valentina</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Institute of Inflammation and Aging, College of Medical and Dental Sciences, University of Birmingham, Queen Elizabeth Hospital, Birmingham B15 2TT, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bobeva</LastName><ForeName>Yoana</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Centre for Neuroscience, Surgery and Trauma, The Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London E1 2AT, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuromuscular Department, Queen Square Motor Neuron Disease Centre, Institute of Neurology, University College London, London WC1N 3BG, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yip</LastName><ForeName>Ping Kei</ForeName><Initials>PK</Initials><Identifier Source="ORCID">0000-0002-3184-9643</Identifier><AffiliationInfo><Affiliation>Centre for Neuroscience, Surgery and Trauma, The Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London E1 2AT, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schmierer</LastName><ForeName>Klaus</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Centre for Neuroscience, Surgery and Trauma, The Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London E1 2AT, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Board Medicine (Neuroscience), The Royal London Hospital, Barts Health NHS Trust, London E1 1BB, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mauro</LastName><ForeName>Claudio</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-3736-0099</Identifier><AffiliationInfo><Affiliation>Institute of Inflammation and Aging, College of Medical and Dental Sciences, University of Birmingham, Queen Elizabeth Hospital, Birmingham B15 2TT, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tree</LastName><ForeName>Timothy</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Immunobiology, School of Immunology and Microbial Sciences, King's College London, London WC2R 2LS, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Henson</LastName><ForeName>Sian Mari</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Translational Medicine and Therapeutics, William Harvey Research Institute, Barts and the London, Queen Mary University of London, London EC1M 6BQ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Malaspina</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Centre for Neuroscience, Surgery and Trauma, The Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London E1 2AT, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuromuscular Department, Queen Square Motor Neuron Disease Centre, Institute of Neurology, University College London, London WC1N 3BG, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>NA</GrantID><Agency>Quell Therapeutics</Agency><Country/></Grant><Grant><GrantID>NA</GrantID><Agency>Wellcome Trust UK</Agency><Country/></Grant><Grant><GrantID>NA</GrantID><Agency>Sanofi</Agency><Country/></Grant><Grant><GrantID>MR/T016736/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>NA</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NA</GrantID><Acronym>MNDA_</Acronym><Agency>Motor Neurone Disease Association</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>NA</GrantID><Agency>Barts Charity UK</Agency><Country/></Grant><Grant><GrantID>TURNER/OCT15/972-797</GrantID><Acronym>MNDA_</Acronym><Agency>Motor Neurone Disease Association</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MGU0536</GrantID><Agency>Barts and The London Charity</Agency><Country/></Grant><Grant><GrantID>NA</GrantID><Agency>GlaxoSmithKline</Agency><Country/></Grant><Grant><GrantID>NA</GrantID><Agency>The ALS Association</Agency><Country/></Grant><Grant><GrantID>NA</GrantID><Agency>NIHR UK</Agency><Country/></Grant><Grant><GrantID>WRO-2018-0065</GrantID><Agency>The Royal College of Anaesthetists</Agency><Country/></Grant><Grant><GrantID>NA</GrantID><Agency>UCB</Agency><Country/></Grant><Grant><GrantID>NA</GrantID><Agency>Imcyse SA</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>03</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007963" MajorTopicYN="N">Leukocytes, Mononuclear</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009000" MajorTopicYN="N">Monocytes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CD11b</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">beta2 integrin</Keyword><Keyword MajorTopicYN="N">monocytes</Keyword></KeywordList><CoiStatement>O. Yildiz, J. Schroth, V. Lombardi, V. Pucino, Y. Bobeva, Ping K. Yip, K. Schmierer, C. Mauro, T. Tree, and S. M. Henson report no disclosures related to submitted work. A. Malaspina has acted as consultant and received personal fees from Roche and Pfizer. He has worked as site investigator and Work-Package Lead on clinical trials funded by EU2020. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript or in the decision to publish the results.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>2</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>3</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>3</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>3</Month><Day>25</Day><Hour>1</Hour><Minute>8</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>3</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35328793</ArticleId><ArticleId IdType="pmc">PMC8952310</ArticleId><ArticleId IdType="doi">10.3390/ijms23063370</ArticleId><ArticleId IdType="pii">ijms23063370</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bede P., Bokde A., Elamin M., Byrne S., McLaughlin R.L., Jordan N., Hampel H., Gallagher L., Lynch C., Fagan A.J., et al. Grey matter correlates of clinical variables in amyotrophic lateral sclerosis (ALS): A neuroimaging study of ALS motor phenotype heterogeneity and cortical focality. J. Neurol. Neurosurg. Psychiatry. 2012;84:766&#x2013;773. doi: 10.1136/jnnp-2012-302674.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2012-302674</ArticleId><ArticleId IdType="pubmed">23085933</ArticleId></ArticleIdList></Reference><Reference><Citation>Proudfoot M., Jones A., Talbot K., Al-Chalabi A., Turner M.R. The ALSFRS as an outcome measure in therapeutic trials and its relationship to symptom onset. Amyotroph. Lateral Scler. Front. Degener. 2016;17:414&#x2013;425. doi: 10.3109/21678421.2016.1140786.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2016.1140786</ArticleId><ArticleId IdType="pmc">PMC4950444</ArticleId><ArticleId IdType="pubmed">26864085</ArticleId></ArticleIdList></Reference><Reference><Citation>Franchignoni F., Mandrioli J., Giordano A., Ferro S., ERRALS Group A further Rasch study confirms that ALSFRS-R does not conform to fundamental measurement requirements. Amyotroph. Lateral Scler. Front. Degener. 2015;16:331&#x2013;337. doi: 10.3109/21678421.2015.1026829.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2015.1026829</ArticleId><ArticleId IdType="pubmed">25916346</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu C.-H., Macdonald-Wallis C., Gray E., Pearce N., Petzold A., Norgren N., Giovannoni G., Fratta P., Sidle K., Fish M., et al. Neurofilament light chain: A prognostic biomarker in amyotrophic lateral sclerosis. Neurology. 2015;84:2247&#x2013;2257. doi: 10.1212/WNL.0000000000001642.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000001642</ArticleId><ArticleId IdType="pmc">PMC4456658</ArticleId><ArticleId IdType="pubmed">25934855</ArticleId></ArticleIdList></Reference><Reference><Citation>Mantovani S., Garbelli S., Pasini A., Alimonti D., Perotti C., Melazzini M., Bendotti C., Mora G. Immune system alterations in sporadic amyotrophic lateral sclerosis patients suggest an ongoing neuroinflammatory process. J. Neuroimmunol. 2009;210:73&#x2013;79. doi: 10.1016/j.jneuroim.2009.02.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jneuroim.2009.02.012</ArticleId><ArticleId IdType="pubmed">19307024</ArticleId></ArticleIdList></Reference><Reference><Citation>Murdock B.J., Bender D.E., Kashlan S.R., Figueroa-Romero C., Backus C., Callaghan B.C., Goutman S.A., Feldman E.L. Increased ratio of circulating neutrophils to monocytes in amyotrophic lateral sclerosis. Neurol. Neuroimmunol. Neuroinflamm. 2016;3:e242. doi: 10.1212/NXI.0000000000000242.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/NXI.0000000000000242</ArticleId><ArticleId IdType="pmc">PMC4897983</ArticleId><ArticleId IdType="pubmed">27308304</ArticleId></ArticleIdList></Reference><Reference><Citation>Murdock B.J., Zhou T., Kashlan S.R., Little R.J., Goutman S., Feldman E.L. Correlation of Peripheral Immunity With Rapid Amyotrophic Lateral Sclerosis Progression. JAMA Neurol. 2017;74:1446&#x2013;1454. doi: 10.1001/jamaneurol.2017.2255.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2017.2255</ArticleId><ArticleId IdType="pmc">PMC5822195</ArticleId><ArticleId IdType="pubmed">28973548</ArticleId></ArticleIdList></Reference><Reference><Citation>McGill R., Steyn F., Ngo S., Thorpe K.A., Heggie S., Ruitenberg M.J., Henderson R.D., McCombe P.A., Woodruff T.M. Monocytes and neutrophils are associated with clinical features in amyotrophic lateral sclerosis. Brain Commun. 2020;2:1&#x2013;11. doi: 10.1093/braincomms/fcaa013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/braincomms/fcaa013</ArticleId><ArticleId IdType="pmc">PMC7530830</ArticleId><ArticleId IdType="pubmed">33033799</ArticleId></ArticleIdList></Reference><Reference><Citation>Kapellos T.S., Bonaguro L., Gem&#xfc;nd I., Reusch N., Saglam A., Hinkley E.R., Schultze J.L. Human Monocyte Subsets and Phenotypes in Major Chronic Inflammatory Diseases. Front. Immunol. 2019;10:2035. doi: 10.3389/fimmu.2019.02035.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.02035</ArticleId><ArticleId IdType="pmc">PMC6728754</ArticleId><ArticleId IdType="pubmed">31543877</ArticleId></ArticleIdList></Reference><Reference><Citation>Geissmann F., Manz M.G., Jung J., Sieweke M.H., Merad M., Ley K. Development of monocytes, macrophages and dendritic cells. Science. 2010;327:656&#x2013;661. doi: 10.1126/science.1178331.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1178331</ArticleId><ArticleId IdType="pmc">PMC2887389</ArticleId><ArticleId IdType="pubmed">20133564</ArticleId></ArticleIdList></Reference><Reference><Citation>Graves M.C., Fiala M., Dinglasan L.A.V., Liu N.Q., Sayre J., Chiappelli F., van Kooten C., Vinters H.V. Inflammation in amyotrophic lateral sclerosis spinal cord and brain is mediated by activated macrophages, mast cells and T cells. Amyotroph. Lateral Scler. 2004;5:213&#x2013;219. doi: 10.1080/14660820410020286.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14660820410020286</ArticleId><ArticleId IdType="pubmed">15799549</ArticleId></ArticleIdList></Reference><Reference><Citation>Henkel J.S., Engelhardt J.I., Sikl&#xf3;s L., Simpson E.P., Kim S.H., Pan T., Goodman J.C., Siddique T., Beers D.R., Appel S.H. Presence of dendritic cells, MCP-1, and activated microglia/macrophages in amyotrophic lateral sclerosis spinal cord tissue. Ann. Neurol. 2003;55:221&#x2013;235. doi: 10.1002/ana.10805.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.10805</ArticleId><ArticleId IdType="pubmed">14755726</ArticleId></ArticleIdList></Reference><Reference><Citation>Butovsky O., Siddiqui S., Gabriely G., Lanser A.J., Dake B., Murugaiyan G., Doykan C.E., Wu P.M., Gali R.R., Iyer L., et al. Modulating inflammatory monocytes with a unique microRNA gene signature ameliorates murine ALS. J. Clin. Investig. 2012;122:3063&#x2013;3087. doi: 10.1172/JCI62636.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI62636</ArticleId><ArticleId IdType="pmc">PMC3428086</ArticleId><ArticleId IdType="pubmed">22863620</ArticleId></ArticleIdList></Reference><Reference><Citation>Zondler L., M&#xfc;ller K., Khalaji S., Bliederh&#xe4;user C., Ruf W.P., Grozdanov V., Thiemann M., Fundel-Clemes K., Freischmidt A., Holzmann K., et al. Peripheral monocytes are functionally altered and invade the CNS in ALS patients. Acta Neuropathol. 2016;132:391&#x2013;411. doi: 10.1007/s00401-016-1548-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-016-1548-y</ArticleId><ArticleId IdType="pubmed">26910103</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao W., Beers D.R., Hooten K.G., Sieglaff D.H., Zhang A., Kalyana-Sundaram S., Traini C.M., Halsey W.S., Hughes A.M., Sathe G.M., et al. Characterization of Gene Expression Phenotype in Amyotrophic Lateral Sclerosis Monocytes. JAMA Neurol. 2017;74:677&#x2013;685. doi: 10.1001/jamaneurol.2017.0357.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2017.0357</ArticleId><ArticleId IdType="pmc">PMC5822209</ArticleId><ArticleId IdType="pubmed">28437540</ArticleId></ArticleIdList></Reference><Reference><Citation>Zondler L., Feiler M.S., Freischmidt A., Ruf W.P., Ludolph A.C., Danzer K.M., Weishaupt J.H. Impaired activation of ALS monocytes by exosomes. Immunol. Cell Biol. 2017;95:207&#x2013;214. doi: 10.1038/icb.2016.89.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/icb.2016.89</ArticleId><ArticleId IdType="pubmed">27616750</ArticleId></ArticleIdList></Reference><Reference><Citation>Baufeld C., O&#x2019;Loughlin E., Calcagno N., Madore C., Butovsky O. Differential contribution of microglia and monocytes in neurodegenerative diseases. J. Neural Transm. 2017;125:809&#x2013;826. doi: 10.1007/s00702-017-1795-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00702-017-1795-7</ArticleId><ArticleId IdType="pmc">PMC7255107</ArticleId><ArticleId IdType="pubmed">29063348</ArticleId></ArticleIdList></Reference><Reference><Citation>Miguel L.I., Almeida C.B., Traina F., Canalli A.A., Dominical V.M., Saad S.T.O., Costa F.F., Conran N. Inhibition of phosphodiesterase 9A reduces cytokine-stimulated in vitro adhesion of neutrophils from sickle cell anemia individuals. Agents Actions. 2011;60:633&#x2013;642. doi: 10.1007/s00011-011-0315-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00011-011-0315-8</ArticleId><ArticleId IdType="pubmed">21336703</ArticleId></ArticleIdList></Reference><Reference><Citation>Nardo G., Pozzi S., Pignataro M., Lauranzano E., Spano G., Garbelli S., Mantovani S., Marinou K., Papetti L., Monteforte M., et al. Amyotrophic Lateral Sclerosis Multiprotein Biomarkers in Peripheral Blood Mononuclear Cells. PLoS ONE. 2011;6:e25545.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3187793</ArticleId><ArticleId IdType="pubmed">21998667</ArticleId></ArticleIdList></Reference><Reference><Citation>Butovsky O., Jedrychowski M.P., Cialic R., Krasemann S., Murugaiyan G., Fanek Z., Greco D.J., Wu P.M., Doykan C.E., Kiner O., et al. Targeting miR-155 restores abnormal microglia and attenuates disease in SOD1 mice. Ann. Neurol. 2014;77:75&#x2013;99. doi: 10.1002/ana.24304.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24304</ArticleId><ArticleId IdType="pmc">PMC4432483</ArticleId><ArticleId IdType="pubmed">25381879</ArticleId></ArticleIdList></Reference><Reference><Citation>Quek H., Cun&#xed;-L&#xf3;pez C., Stewart R., Colletti T., Notaro A., Sun Y., Guo C.C., Lupton M.K., Nguyen T.H., Oikari L.E., et al. ALS monocyte-derived microglia reveal cytoplasmic TDP-43 accumulation, DNA damage, and cell-specific impairment of phagocytosis associated with disease progression. J. Neuroinflamm. 2022;28:2&#x2013;21. doi: 10.1186/s12974-022-02421-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-022-02421-1</ArticleId><ArticleId IdType="pmc">PMC8887023</ArticleId><ArticleId IdType="pubmed">35227277</ArticleId></ArticleIdList></Reference><Reference><Citation>Beers D.R., Zhao W., Wang J., Zhang X., Wen S., Neal D., Thonhoff J.R., Alsuliman A.S., Shpall E.J., Rezvani K., et al. ALS patients&#x2019; regulatory T lymphocytes are dysfunctional, and correlate with disease progression rate and severity. JCI Insight. 2017;2:e89530. doi: 10.1172/jci.insight.89530.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.89530</ArticleId><ArticleId IdType="pmc">PMC5333967</ArticleId><ArticleId IdType="pubmed">28289705</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M., Zhang L., Wang L., Granit V., Statland J., Barohn R., Swenson A., Ravits J., Jackson C., Burns T.M., et al. Validation of serum neurofilaments as prognostic and potential pharmacodynamic biomarkers for ALS. Neurology. 2020;95:e59&#x2013;e69. doi: 10.1212/WNL.0000000000009559.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000009559</ArticleId><ArticleId IdType="pmc">PMC7371380</ArticleId><ArticleId IdType="pubmed">32385188</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M., Wuu J., Lombardi V., Jeromin A., Bowser R., Andersen P.M., Malaspina A. Neurofilaments in pre-symptomatic ALS and the impact of genotype. Amyotroph. Lateral Scler. Front. Degener. 2019;20:538&#x2013;548. doi: 10.1080/21678421.2019.1646769.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2019.1646769</ArticleId><ArticleId IdType="pmc">PMC6768722</ArticleId><ArticleId IdType="pubmed">31432691</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinacker P., Verde F., Fang L., Feneberg E., Oeckl P., Roeber S., Anderl-Straub S., Danek A., Diehl-Schmid J., Fassbender K., et al. Chitotriosidase (CHIT1) is increased in microglia and macrophages in spinal cord of amyotrophic lateral sclerosis and cerebrospinal fluid levels correlate with disease severity and progression. J. Neurol. Neurosurg. Psychiatry. 2017;89:239&#x2013;247. doi: 10.1136/jnnp-2017-317138.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2017-317138</ArticleId><ArticleId IdType="pubmed">29142138</ArticleId></ArticleIdList></Reference><Reference><Citation>Shepheard S.R., Karnaros V., Benyamin B., Schultz D.W., Dubowsky M., Wuu J., Chataway T., Malaspina A., Benatar M., Rogers M.L. Urinary neopterin: A novel biomarker of disease progression in amyotrophic lateral sclerosis. Eur. J. Neurol. 2022;29:990&#x2013;999. doi: 10.1111/ene.15237.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.15237</ArticleId><ArticleId IdType="pmc">PMC8901536</ArticleId><ArticleId IdType="pubmed">34967083</ArticleId></ArticleIdList></Reference><Reference><Citation>Zubiri I., Lombardi V., Bremang M., Mitra V., Nardo G., Adiutori R., Lu C.-H., Leoni E., Yip P., Yildiz O., et al. Tissue-enhanced plasma proteomic analysis for disease stratification in amyotrophic lateral sclerosis. Mol. Neurodegener. 2018;13:60. doi: 10.1186/s13024-018-0292-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-018-0292-2</ArticleId><ArticleId IdType="pmc">PMC6223075</ArticleId><ArticleId IdType="pubmed">30404656</ArticleId></ArticleIdList></Reference><Reference><Citation>Leoni E., Bremang M., Mitra V., Zubiri I., Jung S., Lu C.H., Adiutori R., Lombardi V., Russell C., Koncarevic S., et al. Combined tissue-fluid proteomics to unravel phenotypic variability in amyotrophic lateral sclerosis. Sci. Rep. 2019;9:4478. doi: 10.1038/s41598-019-40632-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-019-40632-4</ArticleId><ArticleId IdType="pmc">PMC6418138</ArticleId><ArticleId IdType="pubmed">30872628</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmid M.C., Khan S.Q., Kaneda M.M., Pathria P., Shepard R., Louis T.L., Anand S., Woo G., Leem C., Faridi M.H., et al. Integrin CD11b activation drives anti-tumor innate immunity. Nat. Commun. 2018;9:5379. doi: 10.1038/s41467-018-07387-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-018-07387-4</ArticleId><ArticleId IdType="pmc">PMC6300665</ArticleId><ArticleId IdType="pubmed">30568188</ArticleId></ArticleIdList></Reference><Reference><Citation>Varga G., Balkow S., Wild M.K., Stadtbaeumer A., Krummen M., Rothoeft T., Higuchi T., Beissert S., Wethmar K., Scharffetter-Kochanek K., et al. Active MAC-1 (CD11b/CD18) on DCs inhibits full T-cell activation. Blood. 2006;109:661&#x2013;669. doi: 10.1182/blood-2005-12-023044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2005-12-023044</ArticleId><ArticleId IdType="pubmed">17003381</ArticleId></ArticleIdList></Reference><Reference><Citation>Ehirchiou D., Xiong Y., Xu G., Chen W., Shi Y., Zhang L. CD11b facilitates the development of peripheral tolerance by suppressing Th17 differentiation. J. Exp. Med. 2007;204:1519&#x2013;1524. doi: 10.1084/jem.20062292.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20062292</ArticleId><ArticleId IdType="pmc">PMC2118631</ArticleId><ArticleId IdType="pubmed">17562817</ArticleId></ArticleIdList></Reference><Reference><Citation>Schittenhelm L., Hilkens C.M., Morrison V.L. &#x3b2;2 integrins as regulators of dendritic cell, monocyte, and macrophage function. Front. Immunol. 2017;8:1866. doi: 10.3389/fimmu.2017.01866.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2017.01866</ArticleId><ArticleId IdType="pmc">PMC5742326</ArticleId><ArticleId IdType="pubmed">29326724</ArticleId></ArticleIdList></Reference><Reference><Citation>Glass J.D. Neuromuscular Disease: Protecting the nerve terminals. eLife. 2018;7:e35664. doi: 10.7554/eLife.35664.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.35664</ArticleId><ArticleId IdType="pmc">PMC5858932</ArticleId><ArticleId IdType="pubmed">29553367</ArticleId></ArticleIdList></Reference><Reference><Citation>Dadon-Nachum M., Melamed E., Offen D. The &#x201c;dying-back&#x201d; phenomenon of motor neurons in ALS. J. Mol. Neurosci. 2011;43:470&#x2013;477. doi: 10.1007/s12031-010-9467-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12031-010-9467-1</ArticleId><ArticleId IdType="pubmed">21057983</ArticleId></ArticleIdList></Reference><Reference><Citation>Moloney E.B., De Winter F., Verhaagen J. ALS as a distal axonopathy: Molecular mechanisms affecting neuromuscular junction stability in the presymptomatic stages of the disease. Front. Neurosci. 2014;8:252. doi: 10.3389/fnins.2014.00252.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2014.00252</ArticleId><ArticleId IdType="pmc">PMC4132373</ArticleId><ArticleId IdType="pubmed">25177267</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiot A., Lobsiger C.S., Boill&#xe9;e S. New insights on the disease contribution of neuroinflammation in amyotrophic lateral sclerosis. Curr. Opin. Neurol. 2019;32:764&#x2013;770. doi: 10.1097/WCO.0000000000000729.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WCO.0000000000000729</ArticleId><ArticleId IdType="pubmed">31306211</ArticleId></ArticleIdList></Reference><Reference><Citation>Wyss-Coray T., Mucke L. Inflammation in Neurodegenerative Disease&#x2014;A Double-Edged Sword. Neuron. 2002;35:419&#x2013;432. doi: 10.1016/S0896-6273(02)00794-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0896-6273(02)00794-8</ArticleId><ArticleId IdType="pubmed">12165466</ArticleId></ArticleIdList></Reference><Reference><Citation>Glass C.K., Saijo K., Winner B., Marchetto M.C., Gage F.H. Mechanisms Underlying Inflammation in Neurodegeneration. Cell. 2010;140:918&#x2013;934. doi: 10.1016/j.cell.2010.02.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2010.02.016</ArticleId><ArticleId IdType="pmc">PMC2873093</ArticleId><ArticleId IdType="pubmed">20303880</ArticleId></ArticleIdList></Reference><Reference><Citation>Niccoli T., Partridge L., Isaacs A.M. Ageing as a risk factor for ALS/FTD. Hum. Mol. Genet. 2017;26:R105&#x2013;R113. doi: 10.1093/hmg/ddx247.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddx247</ArticleId><ArticleId IdType="pubmed">28977441</ArticleId></ArticleIdList></Reference><Reference><Citation>Heaney G.M.L., David W. Soluble receptors in human disease. J. Leukoc. Biol. 1998;64:135&#x2013;146. doi: 10.1002/jlb.64.2.135.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jlb.64.2.135</ArticleId><ArticleId IdType="pubmed">9715251</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>